HANGZHOU TIGERMED CO. H 1 Market Cap ($604.57 Million)
Market Cap & Net Worth: HANGZHOU TIGERMED CO. H 1 (5HZ1)
HANGZHOU TIGERMED CO. H 1 market cap. HANGZHOU TIGERMED CO. H 1 (F:5HZ1) has a market capitalization of $604.57 Million (€517.12 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #10957 globally and #1279 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HANGZHOU TIGERMED CO. H 1's stock price €4.20 by its total outstanding shares 123124800 (123.12 Million). Also see HANGZHOU TIGERMED CO. H 1 cash flow conversion for how efficiently the company converts equity into cash flow.
HANGZHOU TIGERMED CO. H 1 Market Cap History (2021–2026)
HANGZHOU TIGERMED CO. H 1 market cap history from 2021 to 2026. Data shows change from $889.77 Million to $604.57 Million (-13.66% CAGR). Check HANGZHOU TIGERMED CO. H 1 stock price for real-time trading data and today's change.
HANGZHOU TIGERMED CO. H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HANGZHOU TIGERMED CO. H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 5HZ1 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.10x
HANGZHOU TIGERMED CO. H 1's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.74x
HANGZHOU TIGERMED CO. H 1's market cap is 0.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $889.77 Million | $5.21 Billion | $2.87 Billion | 0.17x | 0.31x |
| 2022 | $969.12 Million | $7.09 Billion | $2.01 Billion | 0.14x | 0.48x |
| 2023 | $514.39 Million | $7.38 Billion | $2.02 Billion | 0.07x | 0.25x |
| 2024 | $526.84 Million | $6.60 Billion | $405.14 Million | 0.08x | 1.30x |
| 2025 | $653.51 Million | $6.83 Billion | $887.89 Million | 0.10x | 0.74x |
Competitor Companies of 5HZ1 by Market Capitalization
Companies near HANGZHOU TIGERMED CO. H 1 in the global market cap rankings as of November 4, 2026. Also see balance sheet size of HANGZHOU TIGERMED CO. H 1 for a full breakdown of the balance sheet.
Key companies related to HANGZHOU TIGERMED CO. H 1 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $161.03 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #493 globally with a market cap of $54.62 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #539 globally with a market cap of $50.18 Billion USD ( CN¥342.92 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $682.65 |
| #143 | Danaher Corporation | NYSE:DHR | $161.03 Billion | $227.97 |
| #493 | Natera Inc | NASDAQ:NTRA | $54.62 Billion | $378.92 |
| #539 | WuXi AppTec Co Ltd | SHG:603259 | $50.18 Billion | CN¥138.65 |
Market Capitalization of HANGZHOU TIGERMED CO. H 1 (2021–2026)
Market capitalization of HANGZHOU TIGERMED CO. H 1 from 2021 to today. Between 2021 and today, HANGZHOU TIGERMED CO. H 1's market cap moved from $889.77 Million to $ 604.57 Million, with a yearly change of -13.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €604.57 Million | -7.49% |
| 2025 | €653.51 Million | +24.04% |
| 2024 | €526.84 Million | +2.42% |
| 2023 | €514.39 Million | -46.92% |
| 2022 | €969.12 Million | +8.92% |
| 2021 | €889.77 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of HANGZHOU TIGERMED CO. H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $604.57 Million USD |
| MoneyControl | $604.57 Million USD |
| MarketWatch | $604.57 Million USD |
| marketcap.company | $604.57 Million USD |
| Reuters | $604.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more